Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Proceedings Article"'
Publikováno v:
Journal of Musculoskeletal & Neuronal Interactions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6db0e0ed466978bd29d08f7286ed8afc
https://pubmed.ncbi.nlm.nih.gov/29504586
https://pubmed.ncbi.nlm.nih.gov/29504586
Autor:
Jeffrey M. Brunstrom
Publikováno v:
International Journal of Obesity (2005)
It is widely accepted that meal size is governed by psychological and physiological processes that generate fullness towards the end of a meal. However, observations of natural eating behaviour suggest that this preoccupation with within-meal events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9d901b696a273d71da2f93c3e19c7d
https://doi.org/10.1038/ijo.2014.83
https://doi.org/10.1038/ijo.2014.83
Autor:
Christina A. Roberto, Neha Khandpur
Publikováno v:
International Journal of Obesity (2005)
Accurate and easy-to-understand nutrition labeling is a worthy public health goal that should be considered an important strategy among many to address obesity and poor diet. Updating the Nutrition Facts Panel on packaged foods, developing a uniform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6dc380875a454ff84d448bd96daab09
https://doi.org/10.1038/ijo.2014.86
https://doi.org/10.1038/ijo.2014.86
Autor:
Jason Riis
Publikováno v:
International Journal of Obesity (2005)
This paper uses the frameworks and evidence from marketing and behavioral economics to highlight the opportunities and barriers for portion control in food service environments. Applying Kahneman's ‘thinking fast and slow' concepts, it describes 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b02a5b6d7cc533c23114265baf0d113
https://doi.org/10.1038/ijo.2014.85
https://doi.org/10.1038/ijo.2014.85
Autor:
Barbara J. Rolls
Publikováno v:
International Journal of Obesity (2005)
Systematic studies have shown that providing individuals with larger portions of foods and beverages leads to substantial increases in energy intake. The effect is sustained over weeks, supporting the possibility that large portions have a role in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2608ba8d5d62c2d889f88054f0c19a
https://doi.org/10.1038/ijo.2014.82
https://doi.org/10.1038/ijo.2014.82
Publikováno v:
Leukemia supplements. 1(Suppl 2)
Although chronic myeloid leukemia (CML) is now defined on the basis of the presence of the BCR-ABL1 fusion gene, which may or may not be the initial genetic event that triggers the inappropriate expansion of the myeloid cell mass, CML, similar to oth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64dfefd0dfab7897ec587468008e0f78
https://pubmed.ncbi.nlm.nih.gov/27175247
https://pubmed.ncbi.nlm.nih.gov/27175247
Autor:
M Montillo
Publikováno v:
Leukemia supplements. 1(Suppl 2)
Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94fbcf5c48eb5b2061ccebff37656472
https://pubmed.ncbi.nlm.nih.gov/27175242
https://pubmed.ncbi.nlm.nih.gov/27175242
Publikováno v:
Leukemia supplements. 1(Suppl 2)
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for treatment. This heterogeneity of clinical cour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9fa3b3cebad9c4baf552c54bd4a87e
https://pubmed.ncbi.nlm.nih.gov/27175240
https://pubmed.ncbi.nlm.nih.gov/27175240
Autor:
M Baccarani
Publikováno v:
Leukemia supplements. 1(Suppl 2)
The first-line treatment of chronic myeloid leukemia is based on the three currently available tyrosine kinase inhibitors (TKIs), namely imatinib, nilotinib and dasatinib. Nilotinib and dasatinib are more potent, and it is predicted that, in comparis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7159a340d71ba247138364e3d96c2906
https://pubmed.ncbi.nlm.nih.gov/27175245
https://pubmed.ncbi.nlm.nih.gov/27175245